Use Of A Simultaneous Integrated Boost For Dose Escalation In Patients With Esophageal Cancer: Initial Safety Data From A Phase I Trial | 3539
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Use of a simultaneous integrated boost for dose escalation in patients with esophageal cancer: Initial safety data from a phase I trial

2nd International Conference on Gastroenterology & Urology

James W. Welsh

AcceptedAbstracts: J Gastrointest Dig Syst

DOI: 10.4172/2161-069X.S1.019

Background: We previously showed that 75% of radiation treatment failures in patients with unresectable esophageal cancer appear within the gross tumor volume (GTV) and that use of a simultaneous integrated boost (SIB) could be used to escalate the radiation dose to the GTV. Based on this work a phase I trial was initiated at MD Anderson to find the maximum tolerated dose (MTD) of such a boost. MTD was defined as the highest dose associated with grade 3-4 esophagitis rates of ≥30%; esophagitis was scored according to V3 of the Common Terminology Criteria for Adverse Events. Initial findings from this trial are presented here. Methods: This study opened in February 2010 and enrolled 15 patients with unresectable esophageal cancer (10 men, 5 women) with good performance status (Karnofsky score ≥70). Patients were treated with concurrent chemotherapy (docetaxel and 5-fluorouracil) and radiation to a dose of 50.4 Gy given in 28 daily 1.8-Gy fractions to the planning target volume (PTV) via intensity-modulated radiation therapy (IMRT). The dose to the gross tumor volume (GTV, defined with endoscopic ultrasonography, positron emission tomography, or computed tomography) was limited to ≤10 cm of esophageal length. Dose to the GTV was to be escalated via SIB starting at 2.1 Gy per day and increasing to 2.25 Gy per day in a 3 ? 3 dose-escalation design. Corrections were made for lung heterogeneity on all treatment plans. Results: All 15 patients (median age 65 y; mean age for men 62.2, mean age for women 63.2 y) completed SIB-IMRT. Three patients received a GTV boost dose of 58.8 Gy, and the other 12 patients received the highest planned boost dose of 63 Gy. Six patients had acute grade 2 esophageal toxicity, three acute grade 3 esophageal toxicity (all prior to starting radiation), and none had grade 4 or 5 treatment-related esophageal toxicity. Two patients experienced late esophageal toxicity (stricture requiring dilation). Seven patients had feeding tubes placed, all prior to radiation. At a median follow-up interval of 21 months, 12 patients were alive, 4 with recurrent disease. One patient underwent esophagectomy after completing the radiation therapy, and no viable tumor was identified. Conclusions: Early findings suggest that an SIB to the GTV for unresectable esophageal cancer was well tolerated, with toxicity comparable to that of historical control subjects. Longer follow-up is needed to assess potential benefits in local control or surviv